Raymond James & Associates Galectin Therapeutics Inc Transaction History

Raymond James & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$2.07 - $3.8 $27,108 - $49,764	-13,096 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$2.59 - $4.15 $33,918 - $54,348	13,096 New	13,096 $51,000
Q4 2020 Feb 12, 2021	SELL	$2.24 - $2.87 $62,137 - $79,613	-27,740 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$2.79 - $4.32 $1,813 - $2,808	650 Added 2.4%	27,740 $79,000
Q3 2019 Nov 07, 2019	BUY	$3.0 - $4.05 $81,270 - $109,714	27,090 New	27,090 $99,000
Q1 2018 May 14, 2018	SELL	$3.78 - $5.97 $68,380 - $107,997	-18,090 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$1.54 - $3.34 $27,858 - $60,420	18,090	18,090 $60,000

112

9.93M

3.78M

5.27M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $94.5M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.